Tag
Sun Pharmaceutical Industries Limited
11 articles
Sun Pharma is undergoing significant changes, highlighted by its agreement to acquire Organon for $11.75 billion, a transformative deal expected to create a top-25 global pharmaceutical company with $12.4 billion in combined revenue and expand its presence into biosimilars and women’s health. The company also recently appointed Dr. Andreas Busch as an Independent Director and Satyavati Berera to its Board, while Rama Bijapurkar is retiring. Sun Pharma will announce its Q4 FY26 results on May 22, 2026, and the trading window has been closed to prevent insider trading. Additionally, the company incorporated a new U.S. subsidiary, Sun Pharma America, Inc., for internal restructuring purposes.
Sun Pharma Receives Promoter Group Reclassification Requests for 1.8% Stake
Sun Pharma received requests on 14 May 2026 from three promoter group members seeking reclassification to public category.
The shareholders, Sudhir Valia, Raksha Valia, and Krishna Valia, collectively
Sun Pharma Q4 FY26 Results Announcement on May 22
Sun Pharma will announce Q4 FY26 results on May 22, 2026, followed by an earnings conference call at 6:30 PM IST.
The hour-long call will feature senior management discussing quarterly performance and
Sun Pharma Appoints Dr. Andreas Busch as Independent Director
Sun Pharma's Board appointed Dr. Andreas Busch as an Independent Director for a five-year term effective 12 May 2026, subject to shareholder approval.
Ms. Rama Bijapurkar will retire from the Board on
Sun Pharma Board Meeting May 22 for FY26 Results, Dividend
Sun Pharma board meeting scheduled for May 22, 2026 to approve Q4 and FY26 audited standalone and consolidated financial results.
Board to consider recommendation of final dividend for FY 2025-26 subj
Sun Pharma Appoints Satyavati Berera Independent Director
Sun Pharmaceutical shareholders approved the appointment of Ms. Satyavati Berera as an Independent Director via postal ballot.
Ms. Berera's term is for five years, effective from 08 May 2026.
The voti
Sun Pharma Acquires Organon for $11.75 Billion
Sun Pharma announced the definitive agreement to acquire Organon for an enterprise value of $11.75 billion, funded by $2-2.5B cash and debt.
The acquisition transforms Sun into a top 25 global pharma
Sun Pharma Investor Call on Organon Acquisition
Sun Pharma disclosed an investor call audio recording regarding its acquisition of Organon & Co.
The call was held on 27 April 2026 and is available on the company's investor relations website.
The di
Sun Pharma Announces Organon Acquisition for Global Expansion
Sun Pharma announces a transformative acquisition of Organon to create a global pharmaceutical leader with significant scale.
The deal adds Women's Health and Biosimilars as new growth platforms and p
Sun Pharma Investor Call on Organon Acquisition
Sun Pharma schedules investor call for today to discuss acquisition of Organon & Co.
Call will be held via video conference at 8:00 AM IST on 27 April 2026.
Senior management will provide updates on t
Sun Pharma Acquires Organon for $11.75 Billion
Sun Pharma enters definitive agreement for all-cash acquisition of Organon at an enterprise value of $11.75 billion, paying $14.00 per share.
The acquisition, subject to regulatory and stockholder app
Sun Pharma Incorporates US Subsidiary Sun Pharma America
Sun Pharmaceutical Industries incorporated a new 100% subsidiary, Sun Pharma America, Inc., in the United States on April 23, 2026.
The incorporation is for internal group structuring purposes and fal